Abstract:Objective To explore the effect of Racecadotril Granules combined with Ribavirin in the treatment of infantile Rotavirus enteritis.Methods A total of 80 children with Rotavirus enteritis treated in our hospital from January to December 2016 were selected as the research subjects,and divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The children in the control group were treated with Ribavirin,and the children in the observation group were treated with Racecadotril Granules on the basis of the control group.After treatment,the clinical effects of the two groups were observed and compared.Results The fever time,diarrhea time,antiemetic time and treatment time in the observation group were shorter than those in the control group,the differences between the two groups of clinical symptoms improvement time and treatment time were statistically significant(P<0.05).The negative rate of Rotavirus in the observation group (87.5%)was higher than that in the control group (45.0%),and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Racecadotril Granules combined with Ribavirin for the treatment of Rotavirus enteritis in children has a good clinical effect.It is better than the only child with Ribavirin treatment for children with Rotavirus enteritis,and it is highly safe and worthy of clinical application.
Raes M,Strens D,Kleintjens J,et al.Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirusvaccinationandthesubsequentswitchfromlyophilized to liquid formulation of Rotarix?[J].Epidemiol Infect,2016,144(14):3017-3024.
[14]
Yen C,Healy K,Tate J E,et al.Rotavirus vaccination and intussusception-Science,surveillance,and safety:a review of evidence and recommendations for future research priorities in low and middle income countries[J].Human Vaccines,2016,12(10):2580-2589.